These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1049 related articles for article (PubMed ID: 29254698)

  • 1. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
    Front Immunol; 2022; 13():807271. PubMed ID: 35173722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
    Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
    Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of neuroblastoma cells through Kynurenine-AHR pathway inhibition.
    Dos Santos IL; Mitchell M; Nogueira PAS; Lafita-Navarro MC; Perez-Castro L; Eriom J; Kilgore JA; Williams NS; Guo L; Xu L; Conacci-Sorrell M
    FEBS J; 2024 May; 291(10):2172-2190. PubMed ID: 38431776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
    Sari S; Tomek P; Leung E; Reynisson J
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic potential of targeting tryptophan catabolism in cancer.
    Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
    Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
    Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
    Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and evaluation of L- and D-5-[
    Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
    Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
    Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
    Front Immunol; 2022; 13():832263. PubMed ID: 35371054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.
    Guastella AR; Michelhaugh SK; Klinger NV; Fadel HA; Kiousis S; Ali-Fehmi R; Kupsky WJ; Juhász C; Mittal S
    J Neurooncol; 2018 Sep; 139(2):239-249. PubMed ID: 29667084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.
    Mazarei G; Budac DP; Lu G; Adomat H; Tomlinson Guns ES; Möller T; Leavitt BR
    J Neurochem; 2013 Dec; 127(6):852-67. PubMed ID: 23786539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evading immunity: new enzyme implicated in cancer.
    Garber K
    J Natl Cancer Inst; 2012 Mar; 104(5):349-52. PubMed ID: 22349199
    [No Abstract]   [Full Text] [Related]  

  • 18. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
    Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
    Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico discovery and therapeutic potential of IDO1 and TDO2 inhibitors.
    Jernigan FE; Sun L
    Future Med Chem; 2017 Aug; 9(12):1309-1311. PubMed ID: 28771034
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.